Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.
- Published In:
- Expert opinion on investigational drugs, 17(8), 1225-35 (2008)
- Authors:
- Reardon, David A, Nabors, L Burt, Stupp, Roger, Mikkelsen, Tom
- Database ID:
- RPEP-01407
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01407APA
Reardon, David A; Nabors, L Burt; Stupp, Roger; Mikkelsen, Tom. (2008). Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.. Expert opinion on investigational drugs, 17(8), 1225-35. https://doi.org/10.1517/13543784.17.8.1225
MLA
Reardon, David A, et al. "Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme.." Expert opinion on investigational drugs, 2008. https://doi.org/10.1517/13543784.17.8.1225
RethinkPeptides
RethinkPeptides Research Database. "Cilengitide: an integrin-targeting arginine-glycine-aspartic..." RPEP-01407. Retrieved from https://rethinkpeptides.com/research/reardon-2008-cilengitide-an-integrintargeting-arginineglycineaspartic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.